Azitra Inc (AZTR)

In January 2026, Azitra, Inc. was scheduled to present at the Biotech Showcase. In December 2025, the company received notice of acceptance of its listing standards compliance plan from NYSE American and must regain compliance by April 1, 2027. In November 2025, Azitra announced a $1.5 million private placement and reported Q3 2025 results with an EPS of -$0.67, exceeding expectations, and addressed a false report regarding the sale of securities. In October 2025, Azitra announced positive preclinical data for ATR-01 and withdrew a follow-on equity offering. In August 2025, Azitra announced Q2 2025 results, initial safety results, 50% enrollment in the Phase 1b trial for ATR-12, and the first patient dosed in the Phase 1/2 trial for ATR-04. The share price has experienced significant volatility and a substantial decline over the past year.

There is no indication of significant demand seasonality for Azitra, Inc.'s products or services based on the available information, as demand is primarily driven by the prevalence of specific dermatological conditions and the progress of its clinical trials.

Azitra, Inc. is a clinical biopharmaceutical company specializing in precision dermatology, operating within the Healthcare sector. It focuses on developing innovative therapies for skin diseases using engineered proteins and topical live biotherapeutic products. Its pipeline includes ATR-12 for Netherton syndrome, ATR-04 for EGFRi therapy rash (with FDA Fast Track designation), and ATR-01 for ichthyosis vulgaris, for which positive preclinical data was announced in October 2025.

Azitra, Inc. is headquartered in Branford, Connecticut, United States. Clinical trial sites for ATR-12 include Yale University and Stanford University. Azitra also has a collaboration with Bayer.

Azitra, Inc. positions itself as a pioneer in genetically engineered bacteria and proteins for therapeutic use in dermatology. Positive developments like announcing positive preclinical data for ATR-01, initial safety results and enrollment progress for ATR-12, and receiving Fast Track designation for ATR-04 contribute positively to its scientific and clinical reputation. Challenges such as the notice of non-compliance from NYSE American and the significant decline in stock price could raise concerns about financial stability. The company also addressed a false report regarding the sale of securities in November 2025.

Institutional investors hold 11.16% of Azitra's stock, with major holders including Geode Capital Management, Llc, National Bank Of Canada, UBS Group AG, and others. Individual insiders hold 0.0326% of the shares, while the general public holds 94.5%. Shareholders have experienced substantial dilution in the past year.